Itolizumab · Climatotherapy · Dermatological Care
Psoriasis Treatment in Cuba
Cuba's Center of Molecular Immunology (CIM) developed Itolizumab (Alzumab), a pioneering anti-CD6 monoclonal antibody for moderate to severe psoriasis. Combined with Cuba's favorable climate for climatotherapy and comprehensive dermatological care, international patients access innovative treatment approaches through SMC Salud's coordinated programs in Havana.
Psoriasis — Treatment Video
Cuba's Biotechnology for Dermatological Conditions
Visual Guide
Understanding psoriasis care in Cuba
See the specialized facilities and patient-centered care that define our psoriasis treatment programs.
Specialized Dermatology care in Cuba
Comprehensive international patient coordination in Havana
Clinical Evidence & Outcomes
The science behind psoriasis treatment in Cuba
Our clinical programs are grounded in peer-reviewed research and coordinated with Cuba's biotechnology institutions. Individual results vary and are confirmed during personalized evaluation.
Itolizumab (Alzumab)
Moderate to Severe Psoriasis
Itolizumab is a monoclonal antibody developed by Cuba's Center of Molecular Immunology (CIM) that targets the CD6 receptor on T cells, modulating the immune response involved in psoriasis. It has been studied in moderate to severe plaque psoriasis and represents Cuba's contribution to biologic therapy for dermatological conditions.
Source: CIM — Center of Molecular Immunology
Climatotherapy
Psoriasis Management
Cuba's tropical climate, abundant sunshine, and coastal environments provide natural conditions that can support psoriasis management. Climatotherapy — the therapeutic use of climate and environment — is incorporated into comprehensive treatment programs where medically appropriate.
Source: SMC Salud — Office of Medical Affairs
Comprehensive Dermatological Care
Multidisciplinary Approach
Patients are assessed using the Psoriasis Area and Severity Index (PASI) at admission and throughout treatment to objectively measure progress. The comprehensive approach combines biologic therapy, phototherapy, topical treatments, and psychological support tailored to individual needs.
Source: SMC Salud — Office of Medical Affairs
Outcomes shown reflect published clinical data and aggregate results. Individual results vary based on diagnosis, disease stage, and overall health, and are confirmed during a personalized medical evaluation. This page is for educational purposes and is not a substitute for professional medical advice.
References & Citations
Clinical content on this page is supported by peer-reviewed research and institutional publications. Individual treatment outcomes vary and are confirmed during personalized medical evaluation.
- 1.
World Health Organization. Psoriasis fact sheet. WHO, 2024.
WHO Fact Sheet - 2.
PubMed. Itolizumab clinical trials for psoriasis. National Library of Medicine.
PubMed - 3.
Center of Molecular Immunology (CIM). Itolizumab (Alzumab) development. Havana, Cuba.
Your Treatment Pathway
Psoriasis Care Pathway
A coordinated, step-by-step pathway from pre-travel preparation through treatment in Cuba and post-departure follow-up.
Initial Inquiry & Records Review
Submit your medical records for expert review by our specialist team. Our international coordinators respond within 24–48 hours with an initial assessment.
- Medical records submission via secure portal
- Case review by specialist medical team
- Initial eligibility assessment
Remote Medical Evaluation
Your case is reviewed by the Cuban medical team. Additional tests or imaging may be requested remotely. A personalized treatment plan is developed and shared with you and your home-country physician.
- Specialist remote consultation
- Additional diagnostics if needed
- Personalized treatment plan issued
Program Issuance & Travel Arrangements
SMC Salud issues your official medical program letter. Our coordinators assist with visa application, flight booking, and accommodation — matched to your treatment program and family needs.
- Medical program letter issued
- Visa application support
- Flight & accommodation arranged
Dermatological Treatment Program
Dermatological evaluation with PASI scoring. Treatment may include Itolizumab (Alzumab) biologic therapy, phototherapy (UVB), climatotherapy, and topical treatments — tailored to psoriasis severity and type.
- PASI baseline assessment & dermatological evaluation
- Itolizumab, phototherapy & climatotherapy
- Personalized topical treatment plan
Skin Response & PASI Monitoring
Regular PASI reassessment and photographic tracking of skin response. Psychological support for the emotional impact of chronic skin disease. Maintenance protocols and lifestyle guidance provided for continued management after return home.
- PASI progress tracking & photographic monitoring
- Psychological & quality-of-life support
- Maintenance protocol & lifestyle guidance
Discharge, Report & Follow-up
Comprehensive medical report translated into your language. Take-home medication supply provided. Telemedicine follow-up program arranged so your Cuban medical team stays connected after you return home.
- Translated comprehensive medical report
- Take-home medication supply
- Telemedicine follow-up scheduled
Our Comprehensive Approach
Itolizumab (Alzumab)
Anti-CD6 monoclonal antibody developed by CIM, targeting T-cell activation in moderate to severe psoriasis.
Climatotherapy
Cuba's tropical climate and coastal environments provide natural conditions supportive of psoriasis management.
Phototherapy
Medically supervised UVB phototherapy (narrowband and broadband) as part of comprehensive dermatological care.
Comprehensive Evaluation
Dermatological assessment of psoriasis type, severity (PASI score), joint involvement, and treatment history.
Psychological Support
Counseling for the emotional and quality-of-life impact of chronic skin conditions.
International Coordination
Medical visa, accommodation, interpretation, and 24/7 support throughout the treatment program.
Psoriasis — Treatment & Medication
Treatment Options Available in Cuba
Cuba's Center of Molecular Immunology (CIM) developed Itolizumab (Alzumab), an anti-CD6 monoclonal antibody for moderate to severe psoriasis. Treatment may also include phototherapy and climatotherapy, taking advantage of Cuba's tropical coastal climate. No therapy can cure psoriasis, and not every patient will benefit. Treatment suitability is determined after a dermatological evaluation of psoriasis type, severity (PASI score), and treatment history.
Treatment suitability is determined after medical evaluation. No therapeutic outcome is guaranteed, and not every patient will benefit. Each case is reviewed individually by the medical team.
Psoriasis — Required Documents
Documents for Medical Evaluation
Providing these documents helps our medical team review your case before you travel. You do not need to send every document to begin — send what you have available.
Skin Photographs
Clear images of affected areas
Dermatology Reports
Specialist assessment and diagnosis
Biopsy (if available)
Skin biopsy results, if previously performed
Previous Treatment Records
Prior therapies and their outcomes
Current Medications
All medications and topical treatments used
Recent Laboratory Results
Blood work and relevant test results
Clinical Evidence
Patient Safety
Expert Specialists
International Standards
Frequently Asked Questions
Questions from international patients
Itolizumab (Alzumab) is a monoclonal antibody developed by Cuba's Center of Molecular Immunology (CIM) that targets the CD6 receptor on T cells. By modulating T-cell activation, it helps reduce the inflammatory immune response that drives psoriasis. It has been studied in moderate to severe plaque psoriasis and represents an innovative biologic therapy option.
Find country-specific information, testimonials, and FAQs for your region.
Could This Treatment Be Right for You?
Submit your medical records for review by our medical team. We will assess your case and provide a personalized recommendation. Treatment suitability is determined only after medical evaluation.